PALOREX

PALOREX – Targeted CDK4/6 Inhibitor for HR-Positive, HER2-Negative Breast Cancer

PALOREX is a prescription-based targeted anticancer medicine containing Palbociclib, a Cyclin-Dependent Kinase (CDK) 4/6 inhibitor indicated for the treatment of Hormone Receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer. It is commonly prescribed in combination with aromatase inhibitors or Fulvestrant as part of a personalized hormone therapy regimen.

PALOREX works by selectively blocking CDK4 and CDK6 enzymes that regulate cancer cell division. By inhibiting these enzymes, PALOREX slows the growth and multiplication of breast cancer cells, helping delay disease progression and improve progression-free survival. It has become an important component of modern targeted therapy for advanced breast cancer.

Key Benefits of PALOREX

• Contains Palbociclib, a clinically proven CDK4/6 inhibitor
• Effective in treating HR-positive, HER2-negative advanced breast cancer
• Helps slow the growth and division of cancer cells
• Commonly used in combination with hormone therapy
• Helps delay disease progression
• Supports personalized targeted breast cancer treatment
• Convenient oral capsule formulation
• Used under the supervision of a qualified oncologist

Uses of PALOREX

PALOREX is indicated for the treatment of:

• HR-positive, HER2-negative advanced breast cancer
• Metastatic breast cancer
• Hormone receptor-positive breast cancer
• Combination therapy with aromatase inhibitors
• Combination therapy with Fulvestrant for eligible patients
• Advanced breast cancer requiring targeted CDK4/6 inhibitor therapy

Why Choose PALOREX?

PALOREX offers an advanced targeted treatment option for patients with hormone receptor-positive, HER2-negative breast cancer. Its proven efficacy in combination with endocrine therapy helps improve progression-free survival while maintaining a convenient oral dosing schedule. It is widely trusted by oncologists as a key component of evidence-based breast cancer management.

Important Safety Information

• Prescription-only anticancer medicine.
• Use only under the supervision of a qualified oncologist.
• Regular blood tests are required to monitor blood cell counts during treatment.
• Inform your doctor about liver disease, infections, pregnancy, breastfeeding, or any other medications before starting therapy.
• Avoid self-medication and do not alter the prescribed dosage.
• Keep out of reach of children.